1. Home
  2. CTKB vs SLN Comparison

CTKB vs SLN Comparison

Compare CTKB & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • SLN
  • Stock Information
  • Founded
  • CTKB 1990
  • SLN 1994
  • Country
  • CTKB United States
  • SLN United Kingdom
  • Employees
  • CTKB N/A
  • SLN N/A
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • SLN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTKB Health Care
  • SLN Health Care
  • Exchange
  • CTKB Nasdaq
  • SLN Nasdaq
  • Market Cap
  • CTKB 708.8M
  • SLN 842.4M
  • IPO Year
  • CTKB 2021
  • SLN N/A
  • Fundamental
  • Price
  • CTKB $6.46
  • SLN $7.68
  • Analyst Decision
  • CTKB Strong Buy
  • SLN Strong Buy
  • Analyst Count
  • CTKB 3
  • SLN 4
  • Target Price
  • CTKB $9.17
  • SLN $61.50
  • AVG Volume (30 Days)
  • CTKB 892.8K
  • SLN 568.9K
  • Earning Date
  • CTKB 11-05-2024
  • SLN 11-14-2024
  • Dividend Yield
  • CTKB N/A
  • SLN N/A
  • EPS Growth
  • CTKB N/A
  • SLN N/A
  • EPS
  • CTKB N/A
  • SLN N/A
  • Revenue
  • CTKB $201,210,000.00
  • SLN $21,773,221.00
  • Revenue This Year
  • CTKB $7.85
  • SLN N/A
  • Revenue Next Year
  • CTKB $14.82
  • SLN $104.98
  • P/E Ratio
  • CTKB N/A
  • SLN N/A
  • Revenue Growth
  • CTKB 9.88
  • SLN N/A
  • 52 Week Low
  • CTKB $4.66
  • SLN $5.81
  • 52 Week High
  • CTKB $9.87
  • SLN $27.72
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 58.79
  • SLN 14.27
  • Support Level
  • CTKB $5.68
  • SLN $5.81
  • Resistance Level
  • CTKB $7.26
  • SLN $18.24
  • Average True Range (ATR)
  • CTKB 0.47
  • SLN 1.41
  • MACD
  • CTKB -0.03
  • SLN -1.10
  • Stochastic Oscillator
  • CTKB 53.94
  • SLN 14.98

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Share on Social Networks: